STADA Arzneimittel AG / Key word(s): Miscellaneous
24.03.2014 14:01
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Important items at a glance
- Adjusted EBITDA increases to new record high of Euro 415.2 million (+13
percent) - adjusted EBITDA margin 20.6 percent (previous year: 20.0
percent)
- Group sales rise to Euro 2,014.4 million (+10 percent) and exceed the
two-billion-euro mark
- International expansion of self-pay patient portfolio from high sales
growth in branded products (+19 percent)
- Substantial growth in emerging markets - particularly Russia (+22
percent) and Vietnam (+328 percent)
- Dividend to increase by 32 percent to Euro 0.66 per common share
- 2014 outlook adjusted due to CIS crisis
STADA key figures
<pre>
2013 2012 +/-
Group sales Euro 2,014.4 million Euro 1,837.5 million +10%
Operating profit Euro 251.5 million Euro 202.1 million +24%
Operating profit, adjusted Euro 306.3 million Euro 266.2 million +15%
EBITDA Euro 383.5 million Euro 323.7 million +18%
EBITDA, adjusted Euro 415.2 million Euro 367.4 million +13%
Net income Euro 121.4 million Euro 86.5 million +40%
Net income, adjusted Euro 160.6 million Euro 147.9 million +9%
Earnings per share Euro 2.04 Euro 1.46 +40%
Earnings per share, adjusted Euro 2.70 Euro 2.50 +8%
Proposed dividend Euro 0.66 Euro 0.50 +32%
</pre>
Bad Vilbel, March 24, 2014 - Today, on March 24, 2014, the Executive Board
of STADA Arzneimittel AG confirmed the preliminary figures for financial
year 2013 already published on March 3, 2014 and announced details on the
development of segments as well as the 2014 adjusted outlook.
"The figures for financial year 2013 are within the scope of our
expectations. Our activities in the two market regions of CIS/Eastern
Europe and Asia & Pacific, as well as our strong Branded Products segment,
contributed to the positive development in particular. In light of this, we
recommend a significant dividend increase of 32 percent to Euro 0.66 per
common share", says Hartmut Retzlaff, STADA's Chairman of the Executive
Board.
Development of sales
STADA's Group sales increased in the reporting year by 10 percent to Euro
2,014.4 million (previous year: Euro 1,837.5 million) and thereby amount to
over two billion euros for the first time in Company history.
Sales of the core segment Generics showed a rise of 2 percent to Euro
1,234.8 million in financial year 2013 (previous year: Euro 1,213.1
million). Generics thereby contributed 61.3 percent to Group sales
(previous year: 66.0 percent). Sales of the core segment Branded Products
increased by 19 percent to Euro 708.5 million in 2013 (previous year: Euro
596.2 million). Branded products thus contributed 35.2 percent to Group
sales (previous year: 32.5 percent).
Development of earnings
The development of earnings in financial year 2013 was characterized by an
increase in financial performance as shown by growth in all of the Group's
reported and adjusted key earnings figures.
Reported operating profit recorded a plus of 24 percent to Euro 251.5
million (previous year: Euro 202.1 million). Reported EBITDA increased by
18 percent to Euro 383.5 million (previous year: Euro 323.7 million).
Reported net income recorded an increase of 40 percent to Euro 121.4
million (previous year: Euro 86.5 million).
After adjusting the key earnings figures for influences distorting the
year-on-year comparison resulting from one-time special effects, adjusted
operating profit increased by 15 percent to Euro 306.3 million (previous
year: Euro 266.2 million). Adjusted EBITDA recorded a plus of 13 percent to
Euro 415.2 million (previous year: Euro 367.4 million) and thereby reached
a new record high in STADA company history. Net income, adjusted for
one-time special effects and effects from the measurement of derivative
financial instruments under financial income and expenses, increased by 9
percent to Euro 160.6 million (previous year: Euro 147.9 million).
The net debt to adjusted EBITDA ratio was 3.1 in the reporting year
(previous year: 3.2).
Dividend proposal
On March 3, 2014, the Executive Board already proposed to distribute a
significantly increased dividend as compared to the previous year of Euro
0.66 per common share for financial year 2013 (previous year: Euro 0.50).
This corresponds to a substantial dividend increase of 32 percent. Should
STADA's Annual General Meeting follow this proposal on June 4, 2014, this
corresponds to total dividend payments of Euro 39.8 million (previous year:
Euro 29.6 million).
Development of the market regions
Sales increased in three out of the total of four STADA market regions in
the reporting year.
In the market region Central Europe, sales increased by 5 percent to Euro
858.7 million in financial year 2013 (previous year: Euro 816.0 million).
Sales generated in this market region thereby had a share of 42.6 percent
in Group sales (previous year: 44.4 percent). The sales in Italy, the
United Kingdom, Switzerland and Ireland developed particularly well in the
market region Central Europe in 2013. After regulatory intervention in
2012, sales in Belgium and Spain increasingly stabilized in the course of
the reporting year.
Sales in the market region CIS/Eastern Europe recorded substantial growth
in 2013 of 19 percent to Euro 629.2 million (previous year: Euro 526.5
million). Sales of the market region thereby contributed 31.2 percent to
Group sales (previous year: 28.7 percent). Russia recorded a strong sales
increase in the reporting year of 30 percent applying the exchange rates of
the previous year. In euro, sales grew significantly by 22 percent to Euro
418.8 million despite a negative currency effect of the Russian ruble
(previous year: Euro 343.0 million). In Serbia, sales grew by 6 percent in
financial year 2013 applying the exchange rates of the previous year. In
euro, sales also increased by 6 percent to Euro 86.0 million with a
slightly positive currency effect of the Serbian dinar (previous year: Euro
80.9 million).
In the market region Germany, sales in financial year 2013 decreased by 3
percent to Euro 454.1 million (previous year: Euro 470.0 million). This
development was based on opposing effects. On one hand, the German generics
market recorded a sales decrease, which is primarily based on now fully
expired portfolio agreements as well as a deliberate partial renouncement
of sales from discount agreements for the benefit of operating
profitability. On the other hand, there was a positive effect in connection
with a sale of intangible assets with subsequent back-licensing for further
utilization in sales. Overall, this market region contributed 22.6 percent
to Group sales (previous year: 25.6 percent).
Sales in the market region Asia & Pacific recorded substantial growth in
2013 of 190 percent to Euro 72.4 million (previous year: Euro 25.0
million). The market region contributed 3.6 percent to Group sales
(previous year: 1.3 percent). The growth in the market region Asia &
Pacific was primarily attributable to the sales increase in the Vietnamese
market as a result of the consolidation of Pymepharco and STADA Vietnam as
subsidiaries.
Development, production and procurement
Research and development costs were at Euro 55.7 million in financial year
2013 (previous year: Euro 52.2 million). STADA launched a total of 724
individual products worldwide in the reporting year (previous year: 717
product launches) - thus once again the highest number in Company history.
Outlook
Against the backdrop of the strong devaluation of the Russian ruble and the
Ukrainian hryvnia, as well as the uncertainties regarding the future
business development in the context of the current CIS crisis, the
Executive Board no longer expects to completely achieve the outlook for
2014 as published in the context of a long-term prognosis in 2010. STADA
does, however, expect slight growth in Group sales, adjusted EBITDA and
adjusted net income. For reasons of transparency, the adjustments as from
2014 will also include negative currency effects from the devaluation of
the Russian ruble as well as further significant currencies of the market
region CIS/Eastern Europe.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / 61118
Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101
603-506 / E-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.
24.03.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STADA Arzneimittel AG: Successful financial year 2013 - Adjusted EBITDA reaches new record high - Dividend to increase by 32 percent - 2014 outlook adjusted
| Source: EQS Group AG